Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

Key Inclusion Criteria:

• Normal healthy volunteers.
• Females must be of non-childbearing potential.
• If engaged in sexual relations with a female of child-bearing potential, males must be surgically sterile or must be willing to use a highly effective method of contraception throughout their study participation and for at least 6 months after the last dose of study drug.
• Must have 2 regions on lower back/upper buttocks that are free of striae, scars, tattoos, or other skin pathologies.
• Must have no conditions that could increase risk of abnormal or delayed healing.

Key Exclusion Criteria:

• Clinically significant abnormalities in medical history or physical examination.
• Clinically significant abnormalities in laboratory tests at screening.
• History of cutaneous disorder.
• Hemangioma, history of hemangioblastoma, or other known vascular disorder.
• Positive for bloodborne pathogen (hepatitis B, hepatitis C, HIV).
• Use of an investigational drug or device within 28 days prior to Day 1, or use of an investigational biological or oligonucleotide drug within 90 days of Day 1.